DJ Mylan's CEO To Bag $30M Upon Exit From Drugmaker -- Market Talk
11:31 ET - Mylan CEO Heather Bresch will receive a departing compensation package totaling $30.8M when she leaves the drugmaker after its merger with Pfizer's off-patent drug division, according to a regulatory filing made Friday by the new entity. The deal, announced in July, is expected to close next year. The combined company, which estimated its 2020 revenues to be $20B, will be led by Michael Goettler, who runs Pfizer's Upjohn business. Bresch joined Mylan in 1992 and two decades later began leading the company, which is headquartered in the Netherlands but operates out of Pittsburgh. Mylan is known for the EpiPen emergency allergy shot but manufactures generic medicines, too. Pfizer shares are up 1.1% while Mylan shares rise 1.4%. (jared.hopkins@wsj.com; @jaredshopkins)
(END) Dow Jones Newswires
October 28, 2019 11:31 ET (15:31 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
DJ Mylan首席執行官退出製藥商後將獲得3000萬美元--市場談話
根據新實體週五提交的一份監管文件，11：31 ET-Mylan首席執行官希瑟·佈雷施(Heather Bresch)將在與輝瑞(Pfizer)專利外藥物部門合併後離開這家制藥商，屆時她將獲得總計3080萬美元的離職補償方案。這筆交易於今年7月宣佈，預計將於明年完成。合併後的公司預計2020年收入為200億美元，將由負責輝瑞Upjohn業務的邁克爾·戈特勒(Michael Goettler)領導。Bresch於1992年加入Mylan，20年後開始領導該公司，該公司總部設在荷蘭，但在匹茲堡運營。Mylan以EpiPen緊急過敏疫苗而聞名，但也生產仿製藥。輝瑞股價上漲1.1%，而Mylan股價上漲1.4%。(jared.Hopkins@wsj.com；@jaredshopkins)
(完)道瓊斯通訊社
2019年10月28日東部時間11：31(格林威治時間15：31)
版權所有(C)2019Dow Jones&Company，Inc.
